NEA Management Company
Latest statistics and disclosures from NEA Management Company's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CELC, RYTM, ACLX, TRVI, SVRA, and represent 59.95% of NEA Management Company's stock portfolio.
- Added to shares of these 4 stocks: CELC (+$139M), ZBIO (+$29M), X4 Pharmaceuticals, Athira Pharma.
- Started 1 new stock position in Athira Pharma.
- Reduced shares in these 3 stocks: VRNA (-$240M), Bright Health Group Ord (-$18M), OMDA (-$8.1M).
- Sold out of its positions in Bright Health Group Ord, OMDA, VRNA.
- NEA Management Company was a net seller of stock by $-92M.
- NEA Management Company has $2.0B in assets under management (AUM), dropping by 7.62%.
- Central Index Key (CIK): 0001512848
Tip: Access up to 7 years of quarterly data
Positions held by NEA Management Company consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for NEA Management Company
NEA Management Company holds 27 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Celcuity (CELC) | 18.0 | $353M | +64% | 3.5M | 99.74 |
|
| Rhythm Pharmaceuticals (RYTM) | 15.9 | $312M | 2.9M | 107.04 |
|
|
| Arcellx Common Stock (ACLX) | 10.1 | $199M | 3.0M | 65.20 |
|
|
| Trevi Therapeutics (TRVI) | 8.4 | $166M | 13M | 12.52 |
|
|
| Savara (SVRA) | 7.5 | $148M | 25M | 6.03 |
|
|
| Zenas Biopharma (ZBIO) | 6.5 | $128M | +28% | 3.5M | 36.31 |
|
| Monte Rosa Therapeutics (GLUE) | 6.2 | $121M | 7.7M | 15.68 |
|
|
| Mbx Biosciences (MBX) | 5.8 | $114M | 3.6M | 31.54 |
|
|
| Coursera (COUR) | 4.8 | $95M | 13M | 7.36 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 3.2 | $63M | 4.0M | 15.95 |
|
|
| Gossamer Bio (GOSS) | 2.9 | $56M | 18M | 3.10 |
|
|
| CRISPR Therapeutics Namen Akt (CRSP) | 2.8 | $56M | 1.1M | 52.44 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.7 | $34M | 4.1M | 8.18 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.7 | $33M | 2.0M | 16.59 |
|
|
| CVRX (CVRX) | 0.7 | $14M | 2.0M | 7.10 |
|
|
| X4 Pharmaceuticals | 0.7 | $13M | +44% | 3.2M | 4.00 |
|
| Champions Oncology Com New (CSBR) | 0.6 | $12M | 1.7M | 6.91 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.6 | $11M | 4.4M | 2.43 |
|
|
| Korro Bio (KRRO) | 0.4 | $8.7M | 1.1M | 8.01 |
|
|
| Inventiva SA Ads (IVA) | 0.3 | $6.8M | 1.5M | 4.65 |
|
|
| Nkarta (NKTX) | 0.3 | $6.6M | 3.6M | 1.85 |
|
|
| Senti Biosciences Com New (SNTI) | 0.2 | $3.9M | 3.8M | 1.04 |
|
|
| Athira Pharma | 0.2 | $3.5M | NEW | 464k | 7.57 |
|
| Synlogic Com New (SYBX) | 0.2 | $3.3M | 2.9M | 1.12 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.1 | $2.4M | 1.6M | 1.49 |
|
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $1.4M | 479k | 2.90 |
|
|
| Imagenebio (IMA) | 0.0 | $345k | 50k | 6.90 |
|
Past Filings by NEA Management Company
SEC 13F filings are viewable for NEA Management Company going back to 2010
- NEA Management Company 2025 Q4 filed Feb. 17, 2026
- NEA Management Company 2025 Q3 filed Nov. 14, 2025
- NEA Management Company 2025 Q2 filed Aug. 14, 2025
- NEA Management Company 2025 Q1 filed May 14, 2025
- NEA Management Company 2024 Q4 filed Feb. 14, 2025
- NEA Management Company 2024 Q3 filed Nov. 14, 2024
- NEA Management Company 2024 Q2 filed Aug. 14, 2024
- NEA Management Company 2024 Q1 filed May 15, 2024
- NEA Management Company 2023 Q4 filed Feb. 14, 2024
- NEA Management Company 2023 Q3 filed Nov. 14, 2023
- NEA Management Company 2023 Q2 filed Aug. 11, 2023
- NEA Management Company 2023 Q1 filed May 15, 2023
- NEA Management Company 2022 Q4 filed Feb. 10, 2023
- NEA Management Company 2022 Q3 filed Nov. 14, 2022
- NEA Management Company 2022 Q2 filed Aug. 15, 2022
- NEA Management Company 2022 Q1 filed May 16, 2022